Cystografin side effects by duration, gender and age - a phase IV clinical study of FDA data

< 1 month:

1. Drug ineffective
2. Drug administration error
3. Urinary tract infection pseudomonal

1 - 6 months:

n/a

6 - 12 months:

n/a

1 - 2 years:

n/a

2 - 5 years:

n/a

5 - 10 years:

n/a

10+ years:

n/a

not specified:

1. Bone density decreased
2. Anxiety
3. Bone loss
4. Anaphylactoid reaction (type of anaphylaxis that does not involve an allergic reaction but is due to direct mast cell degranulation)
5. Drug ineffective
6. Kidney infection
7. Nausea (feeling of having an urge to vomit)

female:

1. Anxiety
2. Anaphylactoid reaction (type of anaphylaxis that does not involve an allergic reaction but is due to direct mast cell degranulation)
3. Kidney infection
4. Urinary tract infection pseudomonal

male:

1. Bone density decreased
2. Bone loss
3. Drug ineffective
4. Drug administration error
5. Nausea (feeling of having an urge to vomit)

0-1:

1. Urinary tract infection pseudomonal

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

1. Anxiety

40-49:

1. Anaphylactoid reaction (type of anaphylaxis that does not involve an allergic reaction but is due to direct mast cell degranulation)

50-59:

1. Bone loss

60+:

1. Bone density decreased